Hino Haruaki, Maru Natsumi, Utsumi Takahiro, Matsui Hiroshi, Taniguchi Yohei, Saito Tomohito, Kouda Katsuyasu, Murakawa Tomohiro
Department of Thoracic Surgery, Kansai Medical University, 2-5-1 Shinmachi Hirakata, Osaka, 573-1191, Japan.
Department of Hygiene and Public Health, Kansai Medical University, 2-5-1 Shinmachi Hirakata, Osaka, 573-1191, Japan.
Surg Today. 2025 May;55(5):607-617. doi: 10.1007/s00595-024-02939-2. Epub 2024 Sep 21.
Patients with part-solid adenocarcinomas treated by surgery generally have more favorable outcomes than those with pure-solid adenocarcinomas. We conducted this study to understand the effects of the lepidic components and preoperative characteristics on the postoperative survival of patients with part-solid adenocarcinomas.
The subjects of this retrospective study were 313 patients with stage 1 part-solid adenocarcinomas and 634 patients with pure-solid adenocarcinomas, treated at our institution between 2006 and 2020. Propensity score matching was performed to analyze survival in an unmatched cohort (PSM0, n = 313 vs. 634); a matched cohort based on the consolidation diameter (PSM1, n = 217 each); and a matched cohort based on 11 clinical characteristics (PSM2, n = 103 each). Multivariate analysis was also performed. RESULTS: The 5-year overall/recurrence-free survival rates for part-solid and pure-solid adenocarcinomas were 90.2%/79.3% and 80.8%/66.0% in the PSM0 cohort (P < 0.0001), 87.4%/79.2% and 76.3%/68.6% in the PSM1 cohort (P < 0.05), and 91.6%/92.1% and 76.6%/79.0% in the PSM2 cohort (P > 0.05), respectively. Multivariate analysis revealed that male sex (P = 0.04) and the carcinoembryonic antigen value (P < 0.0001) were significant factors affecting overall survival, while the carcinoembryonic antigen value (P = 0.0002) and consolidation tumor size (P = 0.002) affected recurrence-free survival. The lepidic component was not related to overall (P = 0.45) or recurrence-free (P = 0.78) survival.
Preoperative factors are strongly associated with "consolidation size", which could be the "representative factor" indicating the malignant potential in adenocarcinomas being consistent with the current eighth edition of the TNM.
接受手术治疗的部分实性腺癌患者通常比纯实性腺癌患者具有更良好的预后。我们开展这项研究以了解伏壁状成分和术前特征对部分实性腺癌患者术后生存的影响。
这项回顾性研究的对象为2006年至2020年在我院接受治疗的313例Ⅰ期部分实性腺癌患者和634例纯实性腺癌患者。进行倾向得分匹配以分析未匹配队列(PSM0,n = 313对634)、基于实变直径的匹配队列(PSM1,每组n = 217)以及基于11项临床特征的匹配队列(PSM2,每组n = 103)中的生存率。还进行了多因素分析。结果:在PSM0队列中,部分实性和纯实性腺癌的5年总生存率/无复发生存率分别为90.2%/79.3%和80.8%/66.0%(P < 0.0001),在PSM1队列中分别为87.4%/79.2%和76.3%/68.6%(P < 0.05),在PSM2队列中分别为91.6%/92.1%和76.6%/79.0%(P > 0.05)。多因素分析显示,男性(P = 0.04)和癌胚抗原值(P < 0.0001)是影响总生存的显著因素,而癌胚抗原值(P = 0.0002)和实变肿瘤大小(P = 0.002)影响无复发生存。伏壁状成分与总生存(P = 0.45)或无复发生存(P = 0.78)无关。
术前因素与“实变大小”密切相关,“实变大小”可能是与当前第八版TNM一致的腺癌恶性潜能的“代表性因素”。